Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 9/20 | 0.43 |
| ▸ | DPP7 | Q9UHL4 | 6/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.43 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.38 |
| ▸ | MC4R | P32245 | 1/20 | 0.38 |
| ▸ | CCR5 | P51681 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6841895 | 0.83 | CCR5 (0.53) | KCNH2HRH3PTGDR2CCR5 | |
| SCHEMBL2909495 | 0.81 | CCR5 (0.53) | KCNH2HRH3LMNASMN1; SMN2PTGDR2 | |
| SCHEMBL2916843 | 0.75 | CCR5 (0.57) | KCNH2HRH3PTGDR2CCR5 | |
| SCHEMBL2916232 | 0.72 | CCR5 (0.52) | KCNH2HRH3MCHR1PTGDR2CCR5 | |
| SCHEMBL2910485 | 0.69 | CCR5 (0.65) | KCNH2HRH3CCR5 | |
| SCHEMBL23502083 | 0.68 | HRH3 (0.46) | DPP4KCNH2DPP9HRH3MCHR1 | |
| SCHEMBL13934302 | 0.68 | HRH3 (0.46) | DPP4KCNH2DPP9HRH3MCHR1 | |
| Hydrochloric Acid SCHEMBL2917628 | 0.68 | CCR5 (0.64) | KCNH2HRH3CCR5 | |
| SCHEMBL2909484 | 0.65 | CCR5 (0.55) | KCNH2HRH3PTGDR2CCR5 | |
| Hydrochloric Acid SCHEMBL2916236 | 0.65 | CCR5 (0.55) | KCNH2HRH3PTGDR2CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6673829-B2 | TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM, THE PERIPHERAL NERVOUS SYSTEM, THE CARDIOVASCULAR SYSTEM, THE PULMONARY SYSTEM, THE GASTROINTESTINAL SYSTEM AND THE ENDOCRINOLOGICAL SYSTEM. | NOVO NORDISK A/S (DK) | 2004-01-06 | — | — | US | disclosed |
| US-20030130253-A1 | Novel aminoazetidine,-pyrrolidine and -piperidine derivatives | VTVX HOLDINGS II LLC | 2003-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130253-A1 | Novel aminoazetidine,-pyrrolidine and -piperidine derivatives | HRH3, HRH1, HRH2 | DPP4 1556/4885DPP7 1571/4885KCNH2 625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.